Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
03/2000
03/29/2000EP0988381A1 T-cell receptor beta-like protein
03/29/2000EP0988380A1 Translational regulator initiation factor 4e-binding protein
03/29/2000EP0988280A1 Hydroxamic acid compounds having anticancer and anti-parasitic properties
03/29/2000EP0988061A1 Methods for delivering bioactive agents
03/29/2000EP0988059A2 Human quinone reductase 2 conjugates for adept and gdept
03/29/2000EP0988057A1 Drug targeting
03/29/2000EP0988056A2 Tissue factor methods and compositions for coagulation and tumor treatment
03/29/2000EP0988047A1 Soluble ctla4 mutant molecules and uses thereof
03/29/2000EP0988042A1 A combination therapy for hiv infections
03/29/2000EP0988028A1 Therapeutically active compositions
03/29/2000EP0988009A1 Device and method for treatment of dysmenorrhea
03/29/2000EP0987997A1 N-methyl-d-aspartate (nmda) receptor blockers for the prevention of atherosclerosis
03/29/2000EP0987943A1 A novel method of detecting and treating cancer
03/29/2000EP0987942A1 Pharmaceutical composition and methods for using it
03/29/2000EP0886526A4 Protection of hemopoietic cells
03/29/2000EP0801554A4 Formulations and methods for reducing skin irritation
03/29/2000EP0783320A4 Protection of hemopoietic cells during chemotherapy or radiotherapy
03/29/2000EP0735868B1 Use of non-steroidal cyclooxygenase inhibitors for the manufacture of a medicament for the treatment of elevated intraocular pressure
03/29/2000EP0697891B1 Polyoxime compounds and their preparation
03/29/2000CN1248917A Method of treating prostatic diseases using active vitamin danalogues
03/29/2000CN1248916A Use of FXR, PPAR 'alpha' and LXR 'alpha' activators to restore barrier function, promote epidermal differentiation and inhibit proliferation
03/29/2000CN1248915A Medicament against infertility and for increasing fertility
03/29/2000CN1248914A Pharmaceutical composition
03/29/2000CN1248912A Oral preparation for prophylactic and therapeutic treatment of helicobacter sp. infection
03/29/2000CN1050763C Process for preparing topical medicinal composition capable of enhancing skin penetration
03/28/2000US6043389 Hydroxy and ether-containing oxyalkylene esters and uses thereof
03/28/2000US6043343 Amino acid sequence; for diagnosis and prevention of cancer and tumors; anticarcinogenic/antitumor agents; for screening compounds which bind to polypeptide
03/28/2000US6043283 Administering tyramine compound to patient to inhibit injury, destruction or death of neurons
03/28/2000US6043273 Compositions, apparatus and methods for facilitating surgical procedures
03/28/2000US6043271 Method for the preparation of (±)-calanolide A and intermediates thereof
03/28/2000US6043255 Muscarinic antagonists
03/28/2000US6043249 The compounds have either a sulfhydryl moiety or are reducible disulfides; antifolates
03/28/2000US6043244 Method and composition for treating migraine
03/28/2000US6043234 Method for treating endometriosis or leiomyomata uteri with a competitive progesterone antagonist and a gestagen
03/28/2000US6043233 Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
03/28/2000US6043091 Compound of 8 to 30 nucleobases targeted to coding region, 3' or 5'-untranslated region, or start codon of nucleic acid encoding a carbohydrate metabolism enzyme; for antidiabetic agents against non-insulin dependent diabetes
03/28/2000US6043071 GlmU
03/28/2000US6043056 Amino acid sequences; for diagnosis, treatment, and prevention of blood, karyotypic, and nervous system disorders
03/28/2000US6043054 Polynucleotides encoding a novel GABA BP polypeptide
03/28/2000US6043053 Wnt-3 polynucleotides
03/28/2000US6043024 Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
03/28/2000US6042847 Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
03/28/2000US6042845 Anti fungal treatment of nails
03/28/2000US6042821 Treating sepsis using chemokines which are a protein or polypeptide
03/28/2000CA2245903A1 Use of pex in the treatment of metabolic bone diseases
03/28/2000CA2180658C Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor
03/28/2000CA2063862C Topical preparation containing a suspension of solid lipid particles
03/23/2000WO2000015845A1 T-type calcium channel
03/23/2000WO2000015826A2 Leptin induced genes
03/23/2000WO2000015806A1 Atp synthase subunit homolog
03/23/2000WO2000015805A1 Use of protein kinase kiaa0551 as pharmaceutical
03/23/2000WO2000015802A1 Moraxella catarrhalis basb034 polypeptides and uses thereof
03/23/2000WO2000015797A2 Compositions and methods for the treatment of immune related diseases
03/23/2000WO2000015794A1 Human cell junction pdz protein
03/23/2000WO2000015793A2 Human gpcr proteins
03/23/2000WO2000015792A2 Promotion or inhibition of angiogenesis and cardiovascularization
03/23/2000WO2000015790A2 Leptin induced genes
03/23/2000WO2000015787A1 Genes encoding for the human and murine death inducer-obliterator-1
03/23/2000WO2000015786A1 Metabotropic gaba receptor complex issued from the central nervous system
03/23/2000WO2000015780A1 Inhibitor of brn-3b and its use for the treatment of breast and ovarian cancer
03/23/2000WO2000015775A1 Rnase p polypeptides
03/23/2000WO2000015770A2 Human serine/threonine protein kinases
03/23/2000WO2000015769A1 Topa
03/23/2000WO2000015766A1 Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent
03/23/2000WO2000015666A2 Compositions and methods for the treatment of tumors
03/23/2000WO2000015639A1 Carboline derivatives as cgmp phosphodiesterase inhibitors
03/23/2000WO2000015273A1 Biologically active implants
03/23/2000WO2000015262A1 Dry powder active agent pulmonary delivery
03/23/2000WO2000015258A1 Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
03/23/2000WO2000015247A2 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
03/23/2000WO2000015246A2 Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto
03/23/2000WO2000015244A2 Pharmaceutical preparation containing a cyclopeptide and a chemotherapeutic agent or an angiogenesis inhibitor
03/23/2000WO2000015233A1 Compositions for the treatment of male erectile dysfunction
03/23/2000WO2000015232A1 Taurolidine and/or taurultam against infectious ulcer or gastritis
03/23/2000WO2000015230A1 METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION
03/23/2000WO2000015229A1 METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION
03/23/2000WO2000015228A1 Combinations of tetracyclic cyclic gmp-specific phosphodiesterase inhibitors with further therapeutic agents
03/23/2000WO2000015221A1 Stable ascorbic acid preparation for topical use
03/23/2000WO2000015217A1 A new composition
03/23/2000WO2000015208A2 New use of immunosupressants for mmp-mediated diseases
03/23/2000WO2000015207A2 Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s)
03/23/2000WO2000015205A2 Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes
03/23/2000WO2000015198A1 Orally administered controlled drug delivery system providing temporal and spatial control
03/23/2000WO2000015195A1 Quick release pharmaceutical compositions of drug substances
03/23/2000WO2000015176A2 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
03/23/2000WO2000015175A2 Use as an active substance of molecules binding to beta-1-integrin with the capacity to kill cells
03/23/2000WO2000015167A1 Anti-inflammatory and antimicrobial uses for bioactive glass compositions
03/23/2000WO2000006135A3 Cholinergic agents in the treatment of presbyopia
03/23/2000WO2000006134A3 Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
03/23/2000WO2000002520A3 T-lymphocyte exchange
03/23/2000WO2000000599A3 Composition for the induction of apoptosis in target cells
03/23/2000WO1999063983A9 MULTIBINDING AGENTS THAT MODULATE PPARη AND RXR RECEPTORS
03/23/2000WO1999061085A3 Method and compositions for treatment of cancers
03/23/2000WO1998015272A8 Method for inhibiting stress-activated protein kinases
03/23/2000WO1996040039A3 Isolated nucleic acid molecules, peptides which form complexes with mhc molecule hla-a2 and uses thereof
03/23/2000DE19842415A1 Pharmaceutical preparation for treating e.g. tumors, thrombosis or inflammation, contains cyclic pentapeptide integrin inhibitor and chemotherapeutic agent and/or angiogenesis inhibitor
03/23/2000CA2344316A1 Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent
03/23/2000CA2344309A1 Method for treating diabetes employing an ap2 inhibitor and combination
03/23/2000CA2344300A1 Method for treating atherosclerosis employing an ap2 inhibitor and combination
03/23/2000CA2344151A1 Pharmaceutical preparation
1 ... 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 ... 1151